<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>College Retirement Equities Fund - Cref Stock Account — News on 6ix</title>
    <link>https://6ix.com/company/college-retirement-equities-fund-cref-stock-account</link>
    <description>Latest news and press releases for College Retirement Equities Fund - Cref Stock Account on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/college-retirement-equities-fund-cref-stock-account" rel="self" type="application/rss+xml" />
    <item>
      <title>Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer</title>
      <link>https://6ix.com/company/college-retirement-equities-fund-cref-stock-account/news/zentalis-pharmaceuticals-announces-abstract-acceptance-at-asco-2026-featuring-azenosertib-in-combination-with-paclitaxel-for-platinum-resistant-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/college-retirement-equities-fund-cref-stock-account/news/zentalis-pharmaceuticals-announces-abstract-acceptance-at-asco-2026-featuring-azenosertib-in-combination-with-paclitaxel-for-platinum-resistant-ovarian-cancer</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis®</description>
    </item>
  </channel>
</rss>